Jazz Pharmaceuticals plc — Director's Dealing 2014

Mar 3, 2014

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2014-02-27

Reporting Person: Tobias Jeffrey K (EVP, Research & Dev and CMO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2014-02-27	Ordinary Shares	S	3000	$165.46	Disposed	41777	Direct
2014-02-27	Ordinary Shares	A	7500	—	Acquired	49277	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2014-02-27	Nonstatutory Stock Option (right to buy)	$166.62	A	14355	Acquired	2014-02-26	Ordinary Shares (14355)	Direct
2014-02-27	Incentive Stock Option (right to buy)	$166.62	A	645	Acquired	2014-02-26	Ordinary Shares (645)	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.30 to $165.5825, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F2: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in four equal annual installments on the anniversary of the grant date, February 27, 2014.

F3: These two options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these two options vest over four years measured from the grant date, February 27, 2014, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter.